ed over transition from $64M market cap to fully integrated biopharmaceutical company with $500M in revenue in 2010. Currently a director of Human Genome Sciences, Zelos and PanOptica. Chairman and CEO of Ambit Biosciences; previously President of Research at Celgene, CEO of Novocell, CEO of Signal Therapeut